Browsing by Author "Panepistimion Patron"

Filter results by typing the first few letters
Now showing 1 - 9 of 9
  • No Thumbnail Available
    PublicationMetadata only
    Correction to: Protective ventilation with high versus low positive end-expiratory pressure during one-lung ventilation for thoracic surgery (PROTHOR): Study protocol for a randomized controlled trial (Trials (2019) 20: 213 DOI: 10.1186/s13063-019-3208-8)
    (2019-05-08) T. Kiss; J. Wittenstein; C. Becker; K. Birr; G. Cinnella; E. Cohen; M. R. El Tahan; L. F. Falcão; C. Gregoretti; M. Granell; T. Hachenberg; M. W. Hollmann; R. Jankovic; W. Karzai; J. Krassler; T. Loop; M. J. Licker; N. Marczin; G. H. Mills; M. T. Murrell; V. Neskovic; Z. Nisnevitch-Savarese; P. Pelosi; R. Rossaint; M. J. Schultz; A. Serpa Neto; P. Severgnini; L. Szegedi; T. Vegh; G. Voyagis; J. Zhong; M. Gama De Abreu; M. Senturk; Fudan University Shanghai Cancer Center; Ospedale Policlinico San Martino; Imam Abdulrahman Bin Faisal university; Medizinische Fakultät und Uniklinikum Magdeburg; University of Niš; Vojnomedicinska Akademija; Centre Hospitalier Universitaire de Charleroi; Panepistimion Patron; Sotiria General Hospital; Dresden University Faculty of Medicine and University Hospital Carl Gustav Carus; Universität Freiburg im Breisgau; Università degli Studi di Genova; Harefield Hospital; Semmelweis Egyetem; Università degli Studi di Foggia; Zentralklinik Bad Berka; Università degli Studi di Palermo; Hospital Israelita Albert Einstein; Imperial College London; Universidade Federal de Sao Paulo; Hospital General Universitario de Valencia; Mahidol University; Istanbul Üniversitesi Tıp Fakültesi; Hôpitaux universitaires de Genève; Fudan University; Università degli Studi dell'Insubria; The Mount Sinai Hospital; Debreceni Egyetem; Universiteit van Amsterdam; University of Sheffield; Amsterdam UMC - University of Amsterdam; Uniklinik RWTH Aachen; Thoracic Center Coswig; Weill Cornell Medicine; Penn State Hershey; Outcomes Research Consortium
    © 2019 The Author(s). After publication of the original article [1], the authors have notified us that two of the collaborator first and last names have been inverted in the "PROTHOR Investigators" table. The correct information is: Surname: Spadaro Name: Savino Surname Vitali Name Costanza The original article has been corrected.
  • No Thumbnail Available
    PublicationMetadata only
    Drug-induced stevens-johnson syndrome and toxic epidermal necrolysis call for optimum patient stratification and theranostics via pharmacogenomics
    (2018-08-31) Chonlaphat Sukasem; Theodora Katsila; Therdpong Tempark; George P. Patrinos; Wasun Chantratita; College of Medicine and Health Sciences United Arab Emirates University; Panepistimion Patron; Chulalongkorn University; Faculty of Medicine, Ramathibodi Hospital, Mahidol University
    Copyright © 2018 by Annual Reviews. All rights reserved. The Global Genomic Medicine Collaborative, a multinational coalition of genomic and policy experts working to implement genomics in clinical care, considers pharmacogenomics to be among the first areas in genomic medicine that can provide guidance in routine clinical practice, by linking genetic variation and drug response. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe life-threatening reactions to medications with a high incidence worldwide. Genomic screening prior to drug administration is a key opportunity and potential paradigm for using genomic medicine to reduce morbidity and mortality and ultimately eliminate one of the most devastating adverse drug reactions. This review focuses on the current understanding of the surveillance, pathogenesis, and treatment of SJS/TEN, including the role of genomics and pharmacogenomics in the etiology, treatment, and eradication of preventable causes of drug-induced SJS/TEN. Gaps, unmet needs, and priorities for future research have been identified for the optimal management of drug-induced SJS/TEN in various ethnic populations. Pharmacogenomics holds great promise for optimal patient stratification and theranostics, yet its clinical implementation needs to be cost-effective and sustainable.
  • No Thumbnail Available
    PublicationMetadata only
    Genomic Medicine Without Borders: Which Strategies Should Developing Countries Employ to Invest in Precision Medicine? A New Fast-Second Winner Strategy
    (2017-11-01) Konstantinos Mitropoulos; David N. Cooper; Christina Mitropoulou; Spiros Agathos; Jürgen K.V. Reichardt; Fatima Al-Maskari; Wasun Chantratita; Ambroise Wonkam; Collet Dandara; Theodora Katsila; Catalina Lopez-Correa; Bassam R. Ali; George P. Patrinos; University of Athens; Cardiff University; The Golden Helix Foundation; Yachay Tech; College of Medicine and Health Sciences United Arab Emirates University; United Arab Emirates University; Mahidol University; University of Cape Town; Panepistimion Patron; Genome British Columbia
    © 2017, Mary Ann Liebert, Inc. Genomic medicine has greatly matured in terms of its technical capabilities, but the diffusion of genomic innovations worldwide faces significant barriers beyond mere access to technology. New global development strategies are sorely needed for biotechnologies such as genomics and their applications toward precision medicine without borders. Moreover, diffusion of genomic medicine globally cannot adhere to a "one-size-fits-all-countries" development strategy, in the same way that drug treatments should be customized. This begs a timely, difficult but crucial question: How should developing countries, and the resource-limited regions of developed countries, invest in genomic medicine? Although a full-scale investment in infrastructure from discovery to the translational implementation of genomic science is ideal, this may not always be feasible in all countries at all times. A simple "transplantation of genomics" from developed to developing countries is unlikely to be feasible. Nor should developing countries be seen as simple recipients and beneficiaries of genomic medicine developed elsewhere because important advances in genomic medicine have materialized in developing countries as well. There are several noteworthy examples of genomic medicine success stories involving resource-limited settings that are contextualized and described in this global genomic medicine innovation analysis. In addition, we outline here a new long-term development strategy for global genomic medicine in a way that recognizes the individual country's pressing public health priorities and disease burdens. We term this approach the "Fast-Second Winner" model of innovation that supports innovation commencing not only "upstream" of discovery science but also "mid-stream," building on emerging highly promising biomarker and diagnostic candidates from the global science discovery pipeline, based on the unique needs of each country. A mid-stream entry into innovation can enhance collective learning from other innovators' mistakes upstream in discovery science and boost the probability of success for translation and implementation when resources are limited. This à la carte model of global innovation and development strategy offers multiple entry points into the global genomics innovation ecosystem for developing countries, whether or not extensive and expensive discovery infrastructures are already in place. Ultimately, broadening our thinking beyond the linear model of innovation will help us to enable the vision and practice of genomics without borders in both developed and resource-limited settings.
  • No Thumbnail Available
    PublicationMetadata only
    Global implementation of genomic medicine: We are not alone
    (2015-06-03) Teri A. Manolio; Marc Abramowicz; Fahd Al-Mulla; Warwick Anderson; Rudi Balling; Adam C. Berger; Steven Bleyl; Aravinda Chakravarti; Wasun Chantratita; Rex L. Chisholm; Vajira H.W. Dissanayake; Michael Dunn; Victor J. Dzau; Bok Ghee Han; Tim Hubbard; Anne Kolbe; Bruce Korf; Michiaki Kubo; Paul Lasko; Erkki Leego; Surakameth Mahasirimongkol; Partha P. Majumdar; Gert Matthijs; Howard L. McLeod; Andres Metspalu; Pierre Meulien; Satoru Miyano; Yaakov Naparstek; P. Pearl O'Rourke; George P. Patrinos; Heidi L. Rehm; Mary V. Relling; Gad Rennert; Laura Lyman Rodriguez; Dan M. Roden; Alan R. Shuldiner; Sukdeb Sinha; Patrick Tan; Mats Ulfendahl; Robyn Ward; Marc S. Williams; John E.L. Wong; Eric D. Green; Geofrey S. Ginsburg; National Human Genome Research Institute; Université libre de Bruxelles (ULB); University of Kuwait; Australian Government; University of Luxembourg; Institute of Medicine - Washington; Intermountain Healthcare; The Johns Hopkins School of Medicine; Mahidol University; Northwestern University Feinberg School of Medicine; University of Colombo Faculty of Medicine; Wellcome Trust; National Academy of Medicine; Korea National Institute of Health; King's College London; National Health Committee; University of Alabama at Birmingham; Riken; McGill University; University of Tartu; Thailand Ministry of Public Health; Indian Statistical Institute, Kolkata; KU Leuven; Moffitt Cancer Center; Genome Canada; Institute of Medical Science The University of Tokyo; Hadassah University Medical Centre; Partners HealthCare; Panepistimion Patron; St. Jude Children's Research Hospital; Carmel Medical Center; Vanderbilt University School of Medicine; University of Maryland School of Medicine; Ministry of Science And Technology, India; Duke-NUS Medical School Singapore; Swedish Research Council; University of Queensland; Geisinger Health System; National University of Singapore; Duke University; Genomics England
    © 2015, American Association for the Advancement of Science. All rights reserved. Around the world, innovative genomic-medicine programs capitalize on singular capabilities arising from local health care systems, cultural or political milieus, and unusual selected risk alleles or disease burdens. Such individual eforts might beneft from the sharing of approaches and lessons learned in other locales. The U.S. National Human Genome Research Institute and the National Academy of Medicine recently brought together 25 of these groups to compare projects, to examine the current state of implementation and desired near-term capabilities, and to identify opportunities for collaboration that promote the responsible practice of genomic medicine. Eforts to coalesce these groups around concrete but compelling signature projects should accelerate the responsible implementation of genomic medicine in eforts to improve clinical care worldwide.
  • No Thumbnail Available
    PublicationMetadata only
    Protective ventilation with high versus low positive end-expiratory pressure during one-lung ventilation for thoracic surgery (PROTHOR): Study protocol for a randomized controlled trial
    (2019-04-11) T. Kiss; J. Wittenstein; C. Becker; K. Birr; G. Cinnella; E. Cohen; M. R. El Tahan; L. F. Falcão; C. Gregoretti; M. Granell; T. Hachenberg; M. W. Hollmann; R. Jankovic; W. Karzai; J. Krassler; T. Loop; M. J. Licker; N. Marczin; G. H. Mills; M. T. Murrell; V. Neskovic; Z. Nisnevitch-Savarese; P. Pelosi; R. Rossaint; M. J. Schultz; A. Serpa Neto; P. Severgnini; L. Szegedi; T. Vegh; G. Voyagis; J. Zhong; M. Gama De Abreu; M. Senturk; Fudan University Shanghai Cancer Center; Ospedale Policlinico San Martino; Imam Abdulrahman Bin Faisal university; Medizinische Fakultät und Uniklinikum Magdeburg; University of Niš; Vojnomedicinska Akademija; Centre Hospitalier Universitaire de Charleroi; Panepistimion Patron; Sotiria General Hospital; Dresden University Faculty of Medicine and University Hospital Carl Gustav Carus; Universität Freiburg im Breisgau; Università degli Studi di Genova; Harefield Hospital; Semmelweis Egyetem; Università degli Studi di Foggia; Zentralklinik Bad Berka; Università degli Studi di Palermo; Hospital Israelita Albert Einstein; Imperial College London; Universidade Federal de Sao Paulo; Hospital General Universitario de Valencia; Mahidol University; Istanbul Üniversitesi Tıp Fakültesi; Hôpitaux universitaires de Genève; Fudan University; Università degli Studi dell'Insubria; The Mount Sinai Hospital; Debreceni Egyetem; Universiteit van Amsterdam; University of Sheffield; Amsterdam UMC - University of Amsterdam; Uniklinik RWTH Aachen; Thoracic Center Coswig; Penn State Hershey; Outcomes Research Consortium; Weill Cornell Medicine
    © 2019 The Author(s). Background: Postoperative pulmonary complications (PPC) may result in longer duration of in-hospital stay and even mortality. Both thoracic surgery and intraoperative mechanical ventilation settings add considerably to the risk of PPC. It is unclear if one-lung ventilation (OLV) for thoracic surgery with a strategy of intraoperative high positive end-expiratory pressure (PEEP) and recruitment maneuvers (RM) reduces PPC, compared to low PEEP without RM. Methods: PROTHOR is an international, multicenter, randomized, controlled, assessor-blinded, two-arm trial initiated by investigators of the PROtective VEntilation NETwork. In total, 2378 patients will be randomly assigned to one of two different intraoperative mechanical ventilation strategies. Investigators screen patients aged 18 years or older, scheduled for open thoracic or video-assisted thoracoscopic surgery under general anesthesia requiring OLV, with a maximal body mass index of 35 kg/m 2 , and a planned duration of surgery of more than 60 min. Further, the expected duration of OLV shall be longer than two-lung ventilation, and lung separation is planned with a double lumen tube. Patients will be randomly assigned to PEEP of 10 cmH 2 O with lung RM, or PEEP of 5 cmH 2 O without RM. During two-lung ventilation tidal volume is set at 7 mL/kg predicted body weight and, during OLV, it will be decreased to 5 mL/kg. The occurrence of PPC will be recorded as a collapsed composite of single adverse pulmonary events and represents the primary endpoint. Discussion: PROTHOR is the first randomized controlled trial in patients undergoing thoracic surgery with OLV that is adequately powered to compare the effects of intraoperative high PEEP with RM versus low PEEP without RM on PPC. The results of the PROTHOR trial will support anesthesiologists in their decision to set intraoperative PEEP during protective ventilation for OLV in thoracic surgery. Trial registration: The trial was registered in clinicaltrials.gov (NCT02963025) on 15 November 2016.
  • No Thumbnail Available
    PublicationMetadata only
    R2d2 Drives Selfish Sweeps in the House Mouse
    (2016-06-02) John P. Didion; Andrew P. Morgan; Liran Yadgary; Timothy A. Bell; Rachel C. McMullan; Lydia Ortiz De Solorzano; Janice Britton-Davidian; Carol J. Bult; Karl J. Campbell; Riccardo Castiglia; Yung Hao Ching; Amanda J. Chunco; James J. Crowley; Elissa J. Chesler; Daniel W. Förster; John E. French; Sofia I. Gabriel; Daniel M. Gatti; Theodore Garland; Eva B. Giagia-Athanasopoulou; Mabel D. Giménez; Sofia A. Grize; Islam Gündüz; Andrew Holmes; Heidi C. Hauffe; Jeremy S. Herman; James M. Holt; Kunjie Hua; Wesley J. Jolley; Anna K. Lindholm; María J. López-Fuster; George Mitsainas; Maria Da Luz Mathias; Leonard McMillan; Maria Da Graça Morgado Ramalhinho; Barbara Rehermann; Stephan P. Rosshart; Jeremy B. Searle; Meng Shin Shiao; Emanuela Solano; Karen L. Svenson; Patricia Thomas-Laemont; David W. Threadgill; Jacint Ventura; George M. Weinstock; Daniel Pomp; Gary A. Churchill; Fernando Pardo Manuel De Villena; The University of North Carolina at Chapel Hill; Université de Montpellier; Jackson Laboratory; Island Conservation; University of Queensland; Università degli Studi di Roma La Sapienza; Tzu Chi University; Elon University; Leibniz-Institut fur Zoo- und Wildtierforschung; National Institute of Environmental Health Sciences; Faculdade de Ciências, Universidade de Lisboa; University of California, Riverside; Panepistimion Patron; Instituto de Biologia Subtropical; University of Zurich; Ondokuz Mayis University Faculty of Science and Arts; National Institute on Alcohol Abuse and Alcoholism; Istituto Agrario San Michele all'Adige; National Museums of Scotland; Island Conservation; Universitat de Barcelona; National Institute of Diabetes and Digestive and Kidney Diseases; Cornell University; Mahidol University; Texas A and M University; Universitat Autònoma de Barcelona; Jackson Laboratory for Genomic Medicine
    © 2016 The Author 2016. Published by Oxford University Press on behalf of the Society for Molecular Biology and Evolution. A selective sweep is the result of strong positive selection driving newly occurring or standing genetic variants to fixation, and can dramatically alter the pattern and distribution of allelic diversity in a population. Population-level sequencing data have enabled discoveries of selective sweeps associated with genes involved in recent adaptations in many species. In contrast, much debate but little evidence addresses whether "selfish" genes are capable of fixation - thereby leaving signatures identical to classical selective sweeps - despite being neutral or deleterious to organismal fitness. We previously described R2d2, a large copy-number variant that causes nonrandom segregation of mouse Chromosome 2 in females due to meiotic drive. Here we show population-genetic data consistent with a selfish sweep driven by alleles of R2d2 with high copy number (R2d2HC) in natural populations. We replicate this finding in multiple closed breeding populations from six outbred backgrounds segregating for R2d2 alleles. We find that R2d2HC rapidly increases in frequency, and in most cases becomes fixed in significantly fewer generations than can be explained by genetic drift. R2d2HC is also associated with significantly reduced litter sizes in heterozygous mothers, making it a true selfish allele. Our data provide direct evidence of populations actively undergoing selfish sweeps, and demonstrate that meiotic drive can rapidly alter the genomic landscape in favor of mutations with neutral or even negative effects on overall Darwinian fitness. Further study will reveal the incidence of selfish sweeps, and will elucidate the relative contributions of selfish genes, adaptation and genetic drift to evolution.
  • No Thumbnail Available
    PublicationMetadata only
    Success stories in genomic medicine from resource-limited countries
    (2015-01-01) Konstantinos Mitropoulos; Hayat Al Jaibeji; Diego A. Forero; Paul Laissue; Ambroise Wonkam; Catalina Lopez-Correa; Zahurin Mohamed; Wasun Chantratita; Ming Ta Michael Lee; Adrian Llerena; Angela Brand; Bassam R. Ali; George P. Patrinos; The Golden Helix Foundation; Maastricht University; College of Medicine and Health Sciences United Arab Emirates University; Universidad Antonio Nariño; Universidad del Rosario; University of Cape Town, Faculty of Health Sciences; Genome Quebec; University of Malaya; Mahidol University; Riken; Academia Sinica, Institute of Biomedical Sciences; Universidad de Extremadura; Panepistimion Patron
    © 2015 Mitropoulos et al. In recent years, the translation of genomic discoveries into mainstream medical practice and public health has gained momentum, facilitated by the advent of new technologies. However, there are often major discrepancies in the pace of implementation of genomic medicine between developed and developing/resource-limited countries. The main reason does not only lie in the limitation of resources but also in the slow pace of adoption of the new findings and the poor understanding of the potential that this new discipline offers to rationalize medical diagnosis and treatment. Here, we present and critically discuss examples from the successful implementation of genomic medicine in resource-limited countries, focusing on pharmacogenomics, genome informatics, and public health genomics, emphasizing in the latter case genomic education, stakeholder analysis, and economics in pharmacogenomics. These examples can be considered as model cases and be readily replicated for the wide implementation of pharmacogenomics and genomic medicine in other resource-limited environments.
  • No Thumbnail Available
    PublicationMetadata only
    Supramolecular Spheres Self-Assembled from Conical Dendrons Are Chiral
    (2019-04-17) Daniela A. Wilson; Katerina A. Andreopoulou; Mihai Peterca; Pawaret Leowanawat; Dipankar Sahoo; Benjamin E. Partridge; Qi Xiao; Ning Huang; Paul A. Heiney; Virgil Percec; Panepistimion Patron; Stony Brook University; Radboud University Nijmegen; Mahidol University; University of Pennsylvania
    © 2019 American Chemical Society. Frank-Kasper phases and liquid quasicrystals self-organize from supramolecular spheres of dendrimers, block copolymers, surfactants and other self-assembling molecules. These spheres are expected to be achiral due to their isotropic shape. Nevertheless, supramolecular spheres from short helical stacks of crown-like dendrimers self-organize a Pm3n cubic (Frank-Kasper A15) phase which exhibits chirality on the macroscopic scale. However, the chirality of classic isotropic supramolecular micellar-like spheres, generated from conical dendrons, is unknown. Here we report a library of second and third generation biphenylpropyl dendrons with chiral groups at their apex that produces single-handed chiral supramolecular spheres. Up to 480 conical dendrons self-assemble to form micellar-like spheres, with a molar mass of up to 1.1 × 106 g/mol, that self-organize into a Pm3n phase with chirality detectable on the macroscopic scale. This demonstration of chirality in micellar-like spheres of a Frank-Kasper phase raises the fundamental question whether micellar-like spheres forming 3D phases generated from other soft matter such as block copolymers, surfactants, and other molecules are chiral.
  • No Thumbnail Available
    PublicationMetadata only
    Synonymization of key pest species within the Bactrocera dorsalis species complex (Diptera: Tephritidae): Taxonomic changes based on a review of 20 years of integrative morphological, molecular, cytogenetic, behavioural and chemoecological data
    (2015-01-01) Mark K. Schutze; Nidchaya Aketarawong; Weerawan Amornsak; Karen F. Armstrong; Antonis A. Augustinos; Norman Barr; Wang Bo; Kostas Bourtzis; Laura M. Boykin; Carlos Cáceres; Stephen L. Cameron; Toni A. Chapman; Suksom Chinvinijkul; Anastasija Chomič; Marc De Meyer; Ellena Drosopoulou; Anna Englezou; Sunday Ekesi; Angeliki Gariou-Papalexiou; Scott M. Geib; Deborah Hailstones; Mohammed Hasanuzzaman; David Haymer; Alvin K.W. Hee; Jorge Hendrichs; Andrew Jessup; Qinge Ji; Fathiya M. Khamis; Matthew N. Krosch; Luc Leblanc; Khalid Mahmood; Anna R. Malacrida; Pinelopi Mavragani-Tsipidou; Maulid Mwatawala; Ritsuo Nishida; Hajime Ono; Jesus Reyes; Daniel Rubinoff; Michael San Jose; Todd E. Shelly; Sunyanee Srikachar; Keng H. Tan; Sujinda Thanaphum; Ihsan Haq; Shanmugam Vijaysegaran; Suk L. Wee; Farzana Yesmin; Antigone Zacharopoulou; Anthony R. Clarke; Queensland University of Technology QUT; Plant Biosecurity Cooperative Research Centre; Mahidol University; Kasetsart University; Lincoln University, New Zealand; International Atomic Energy Agency, Vienna; Panepistimion Patron; USDA Animal and Plant Health Inspection Service (APHIS); Fujian Agriculture and Forestry University; University of Western Australia; Elizabeth Macarthur Agricultural Institute; Thailand Ministry of Agriculture and Cooperatives; Royal Museum for Central Africa; Aristotle University of Thessaloniki; International Centre of Insect Physiology and Ecology Nairobi; USDA Agricultural Research Service, Washington DC; Atomic Energy Research Establishment, Dhaka; University of Hawaii at Manoa; Universiti Putra Malaysia; NSW Department of Primary Industries; University of Queensland; Pakistan Museum of Natural History; Universita degli Studi di Pavia; Sokoine University of Agriculture; Kyoto University; Tan Hak Heng Co.; National Agricultural Research Center; Universiti Kebangsaan Malaysia
    © 2014 The Royal Entomological Society. Bactrocera papayae Drew & Hancock, Bactrocera philippinensis Drew & Hancock, Bactrocera carambolae Drew & Hancock, and Bactrocera invadens Drew, Tsuruta & White are four horticultural pest tephritid fruit fly species that are highly similar, morphologically and genetically, to the destructive pest, the Oriental fruit fly, Bactrocera dorsalis (Hendel) (Diptera: Tephritidae). This similarity has rendered the discovery of reliable diagnostic characters problematic, which, in view of the economic importance of these taxa and the international trade implications, has resulted in ongoing difficulties for many areas of plant protection and food security. Consequently, a major international collaborative and integrated multidisciplinary research effort was initiated in 2009 to build upon existing literature with the specific aim of resolving biological species limits among B. papayae, B. philippinensis, B. carambolae, B. invadens and B. dorsalis to overcome constraints to pest management and international trade. Bactrocera philippinensis has recently been synonymized with B. papayae as a result of this initiative and this review corroborates that finding; however, the other names remain in use. While consistent characters have been found to reliably distinguish B. carambolae from B. dorsalis, B. invadens and B. papayae, no such characters have been found to differentiate the latter three putative species. We conclude that B. carambolae is a valid species and that the remaining taxa, B. dorsalis, B. invadens and B. papayae, represent the same species. Thus, we consider B. dorsalis (Hendel) as the senior synonym of B. papayae Drew and Hancock syn.n. and B. invadens Drew, Tsuruta & White syn.n. A redescription of B. dorsalis is provided. Given the agricultural importance of B. dorsalis, this taxonomic decision will have significant global plant biosecurity implications, affecting pest management, quarantine, international trade, postharvest treatment and basic research. Throughout the paper, we emphasize the value of independent and multidisciplinary tools in delimiting species, particularly in complicated cases involving morphologically cryptic taxa.